Abstract
Nonalcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the westernized world and now represents a worldwide public health problem. NAFLD encompasses a broad spectrum of conditions, ranging from simple steatosis (nonalcoholic fatty liver) to nonalcoholic steatohepatitis (NASH). The latter is recognized as a potentially progressive disease that could lead to cirrhosis, liver failure, and hepatocellular carcinoma. The recent rise in obesity likely explains the NAFLD epidemic worldwide. Recognition of the importance of NAFLD and its strong association with metabolic syndrome has stimulated interest in its putative role in the development of cardiovascular disease (CVD). Recently, accumulating evidence suggests that NAFLD is associated with a significant greater overall mortality, as well as with increased prevalence of CVD, both of which are independent of classical atherosclerotic risk factors. Furthermore, observation studies of natural history of NAFLD have shown that increased age-related mortality of NAFLD patients is attributable to CVD and liver-related diseases such as liver failure and hepatocellular carcinoma. In this paper, we review clinical data to support a strong association between NAFLD and CVD, and discuss possible underlying mechanisms for accelerated atherosclerosis in NAFLD.
Keywords: Nonalcoholic fatty liver disease, cardiovascular disease, atherosclerosis.
Current Pharmaceutical Design
Title:Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Volume: 20 Issue: 14
Author(s): Hideyuki Hyogo, Kazuaki Chayama and Sho-ichi Yamagishi
Affiliation:
Keywords: Nonalcoholic fatty liver disease, cardiovascular disease, atherosclerosis.
Abstract: Nonalcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease in the westernized world and now represents a worldwide public health problem. NAFLD encompasses a broad spectrum of conditions, ranging from simple steatosis (nonalcoholic fatty liver) to nonalcoholic steatohepatitis (NASH). The latter is recognized as a potentially progressive disease that could lead to cirrhosis, liver failure, and hepatocellular carcinoma. The recent rise in obesity likely explains the NAFLD epidemic worldwide. Recognition of the importance of NAFLD and its strong association with metabolic syndrome has stimulated interest in its putative role in the development of cardiovascular disease (CVD). Recently, accumulating evidence suggests that NAFLD is associated with a significant greater overall mortality, as well as with increased prevalence of CVD, both of which are independent of classical atherosclerotic risk factors. Furthermore, observation studies of natural history of NAFLD have shown that increased age-related mortality of NAFLD patients is attributable to CVD and liver-related diseases such as liver failure and hepatocellular carcinoma. In this paper, we review clinical data to support a strong association between NAFLD and CVD, and discuss possible underlying mechanisms for accelerated atherosclerosis in NAFLD.
Export Options
About this article
Cite this article as:
Hyogo Hideyuki, Chayama Kazuaki and Yamagishi Sho-ichi, Nonalcoholic Fatty Liver Disease and Cardiovascular Disease, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990476
DOI https://dx.doi.org/10.2174/13816128113199990476 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Multidisciplinary Pharmaceutical Drug Design Strategies in the Progress of Drug Discovery"
The process of developing a drug is time- and money-consuming, but also fascinating. The development of numerous computational techniques, synthetic methodologies, formulation-based drug discovery, etc. has improved the drug discovery process. The process of developing new drugs is significantly hampered by drug-poor pharmacodynamics and pharmacokinetic problems. To address these challenges, ...read more
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Foods for Health and to Treat Diseases
Current Pediatric Reviews Nutritional and Therapeutic Potential of Spirulina
Current Pharmaceutical Biotechnology Foreword [The Largest Unmet Market: Chronic Diseases of Aging]
Mini-Reviews in Medicinal Chemistry Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Prevalence and Co-prevalence of Comorbidities among Patients with Type 2 Diabetes Mellitus in the MENA Region: A Systematic Review
Current Diabetes Reviews Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company
Current Drug Safety Towards the Design of Social Media to Promote Physical Activity
Recent Advances in Communications and Networking Technology (Discontinued) Infectious Agents and Neurodegenerative Diseases: Exploring the Links
Current Topics in Medicinal Chemistry New Nutritional and Therapeutical Strategies of NEC
Current Pediatric Reviews Classification of Heart Disease Using MFO Based Neural Network on MRI Images
Current Medical Imaging Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design Strain and Strain Rate Imaging by Echocardiography - Basic Concepts and Clinical Applicability
Current Cardiology Reviews The Role of Genetics in Inflammatory Bowel Disease
Current Drug Targets The Impact of Methodology and Confounding Variables on the Association Between Major Depression and Coronary Heart Disease: Review and Recommendations
Current Psychiatry Reviews Hypertension in China: Past, Present, and Future
Current Hypertension Reviews Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction
Current Cardiology Reviews Blockade of Apoptosis by ACE Inhibitors and Angiotensin Receptor Antagonists
Current Pharmaceutical Design Infective Proteins: The Prion Puzzle
Current Protein & Peptide Science